Login to Your Account

GSK, Novartis ink 'supercomplex' $26.65B three-way transaction

By Nuala Moran
Staff Writer

Tuesday, April 22, 2014

LONDON – Novartis AG and Glaxosmithkline plc are exchanging assets in a three-way, "supercomplex" deal that will see Novartis paying $16 billion for GSK's marketed oncology portfolio, while GSK acquires Novartis' vaccines arm for $5.25 billion.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription